Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer.

ABSTRACT: Mass-spectrometry-based analyses have identified a variety of candidate protein biomarkers that might be crucial for epithelial ovarian cancer (EOC) development and therapy response. Comprehensive validation studies of the biological and clinical implications of proteomics are needed to advance them toward clinical use. Using the Deep MALDI method of mass spectrometry, we developed and independently validated (development cohort: n = 199, validation cohort: n = 135) a blood-based proteomic classifier, stratifying EOC patients into good and poor survival groups. We also determined an age dependency of the prognostic performance of this classifier, and our protein set enrichment analysis showed that the good and poor proteomic phenotypes were associated with, respectively, lowe

SUBMITTER: Kasimir-Bauer S 

PROVIDER: S-EPMC7564837 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature